Immuno-Biological Laboratories Co., Ltd. (4570) AI Stock Analysis

• Market Cap: ¥4.36B
• Dividend Yield: N/A
• Average Volume (3M): 23.51K
• Price to Earnings (P/E): 16.9
• Beta (1Y): 0.95
• Revenue Growth: 9.47%
• EPS Growth: 14.00%
• Country: JP
• Employees: 57
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 6.54
• Shares Outstanding: 9,314,590
• 10 Day Avg. Volume: 28,690
• 30 Day Avg. Volume: 23,506
• PEG Ratio: 0.54
• Price to Book (P/B): 2.95
• Price to Sales (P/S): 4.61
• P/FCF Ratio: 36.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 63 Neutral
• Price Target: ¥495.00 ▲(6.45% Upside)

The overall stock score of 63 reflects strong financial performance with improved profitability and sound balance sheet management. However, technical indicators suggest a bearish trend, and the valuation is moderate without a dividend yield to attract income investors. The absence of recent earnings call insights or corporate events limits additional positive or negative influences on the score.

Immuno-Biological Laboratories Co., Ltd. Business Overview & Revenue Model

Company Description

Immuno-Biological Laboratories Co., Ltd. (4570) is a biotechnology company based in Japan, specializing in the development and manufacture of immunological diagnostic products and reagents. The company operates primarily in the healthcare sector, focusing on providing innovative solutions for disease diagnosis and treatment monitoring. Key products include various types of immunoassays, including those for infectious diseases, allergies, and autoimmune disorders, catering to both clinical laboratories and research institutions.

How the Company Makes Money

Immuno-Biological Laboratories generates revenue through the sale of its diagnostic products and reagents to hospitals, clinics, and laboratories. The company's revenue model is based on direct sales of its proprietary immunoassay kits and related products, which are designed to meet the needs of healthcare providers for accurate and timely diagnostics. Additionally, the company may engage in partnerships and collaborations with pharmaceutical firms and research organizations to develop new diagnostic solutions, creating further revenue opportunities. Other potential revenue streams include licensing agreements for its technologies and services related to product training and support for healthcare professionals using its products.

Immuno-Biological Laboratories Co., Ltd. Financial Statement Overview

Summary

Immuno-Biological Laboratories exhibits a commendable financial trajectory with consistent revenue growth, improved profitability, and sound balance sheet management. The company has strong margins and cash flow generation, indicating efficient operations and a successful turnaround from past losses.

Income Statement

Immuno-Biological Laboratories has demonstrated strong revenue growth over the years. The gross profit margin is robust at 64.8% for 2025, indicating efficient cost management. The net profit margin improved significantly to 25.7% in 2025, showing a turnaround from losses in previous years. Both EBIT and EBITDA margins have improved, reflecting better operational efficiency.

Balance Sheet

The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.13 in 2025, indicating prudent leverage. A high equity ratio of 82.0% suggests strong capitalization. The return on equity stands at 16.4%, reflecting improved profitability and efficient use of equity.

Cash Flow

The operating cash flow has increased significantly, supporting positive free cash flow growth. The operating cash flow to net income ratio is 0.74, indicating strong cash generation relative to profitability. The company has shown consistent improvement in cash flow management, enhancing financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	951.89M	969.53M	816.70M	794.62M	647.58M	602.75M
Gross Profit	632.07M	628.34M	517.29M	526.71M	376.70M	346.86M
EBITDA	225.22M	226.55M	128.11M	-332.00M	-249.50M	-309.88M
Net Income	258.63M	249.05M	186.69M	-289.73M	-258.77M	-318.83M
Balance Sheet
Total Assets	1.92B	1.85B	1.62B	1.43B	1.71B	1.84B
Cash, Cash Equivalents and Short-Term Investments	903.75M	825.73M	734.14M	614.16M	508.35M	604.19M
Total Debt	196.94M	204.23M	235.98M	234.99M	234.00M	90.00M
Total Liabilities	343.43M	331.03M	353.27M	355.72M	336.99M	208.76M
Stockholders Equity	1.58B	1.51B	1.27B	1.08B	1.37B	1.63B
Cash Flow
Free Cash Flow	0.00	123.83M	115.11M	26.46M	-93.20M	-207.60M
Operating Cash Flow	0.00	183.50M	133.78M	26.46M	-93.20M	-194.15M
Investing Cash Flow	0.00	-53.66M	-24.50M	30.04M	-155.63M	-17.23M
Financing Cash Flow	0.00	-31.75M	991.00K	991.00K	144.00M	-216.00M

Immuno-Biological Laboratories Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 465.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4570, the sentiment is Negative. The current price of 465 is below the 20-day moving average (MA) of 473.00, below the 50-day MA of 474.28, and below the 200-day MA of 485.58, indicating a bearish trend. The MACD of -1.60 indicates Positive momentum. The RSI at 41.87 is Neutral, neither overbought nor oversold. The STOCH value of 4.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4570.

Immuno-Biological Laboratories Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	―	¥4.36B	16.85	―	―	9.47%	14.00%
4884	―	¥3.06B	―	―	―	-8.56%	-7.26%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4594	―	¥7.24B	―	―	―	1254.76%	33.94%
4881	―	¥4.22B	―	―	―	965.85%	-42.78%
4591	―	¥4.62B	―	―	―	-59.53%	11.70%
4598	―	¥4.96B	―	―	―	―	20.41%